研究業績

学会発表

A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with Bevacizumab following fixed cycles of Bevacizumab plus Paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial


Shoichiro Ohtani, Shigehira Saji, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Yutaka Yamamoto, Takashi Ishikawa, Shigenori Nagai, Hiroshi Yoshibayasi, Koji Matsumoto, Yasuaki Sagara, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Norikazu Masuda, Naruto Taira, Satoshi Morita, Shinji Ohno, Masakazu Toi


2020年10月 第28回日本乳癌学会学術総会 口演 WEB

乳癌術前化学療法におけるアブラキサンの有用性についての大規模統合解析 (JBCRG-S01)


二村学, 大庭真梨, 増田慎三, 中山貴寛, 櫻井健一, 坂東裕子, 岡田守人, 山本豊, 金敬徳, 佐伯俊昭, 長嶋健 桑山隆志, 唐宇飛, 平野明, 井口雅史, 山神和彦, 水野豊, 小島康幸, 八十島宏行, 大野真司


2020年10月 第28回日本乳癌学会学術総会 ポスター WEB

Outcomes of fulvestrant treatment in ER-positive HER2-positive advanced or metastatic breast cancer


Misato Masuyama, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Koji Kaneko, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Tomomi Fujisawa, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Satoshi Morita, Masakazu Toi, Shinji Ohno


2020年10月 第28回日本乳癌学会学術総会 ポスター WEB

Factors associated with prolonged OS in postmenopausal ER-positive advanced breast cancer patients


Koji Kaneko, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Tomomi Fujisawa, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Satoshi Morita, Masakazu Toi, Shinji Ohno


2020年10月 第28回日本乳癌学会学術総会 ポスター WEB

Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer


Yutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, Volkmar Müller, Oleg Gluz, Peter Klare, Bahriye Aktas, Dank Magdolna, László Büdi, Béla Pikó, László Mangel, Masakazu Toi, Satoshi Morita, Shinji Ohno


2020年10月 第28回日本乳癌学会学術総会 口演 WEB

A randomized, phase 2 study of neoadjuvant chemotherapy containing eribulin mesylate for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22)


Hiroko Bando, Norikazu Masuda, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R.Kataoka, Ryuji Uozumi, Shinji Ohno, Masakazu Toi


2020.9 ESMO Oral WEB

Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: a randomized, open-label, phase 2 clinical trial


Shigehira Saji, Naruto Taira, Satoshi Morita, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Tohru Ohtake, Tatsuya Toyama, Yuichiro Kikawa, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Rikiya Nakamura, Yutaka Yamamoto, Uhi Toh, Hiroji Iwata, Norikazu Masuda, Shinji Ohno and Masakazu Toi


2020.9 ESMO Poster WEB

Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer


Hiroyasu Yamashiro, Yutaka Yamamoto, Andreas Schneeweiss, Volkmar Müller, Oleg Gluz, Peter Klare, Bahriye Aktas, Dank Magdolna, László Büdi,Béla Pikó, László Mangel, Masakazu Toi, Satoshi Morita, Shinji Ohno


2020.9 ESMO Poster WEB

Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the Japan Breast Cancer Research Group(JBCRG)-C06 Safari study


Misato Hagi, Hidetoshi Kawaguchi, Norikazu Masuda, Shigehira Saji, Yutaka Yamamoto, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Satoshi Morita, Masakazu Toi, Shinji Ohno


2019.12 SABCS Poster San Antonio, Texas

Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study


Kenjiro Aogi, Hidetosh Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno


2019.12 SABCS Poster San Antonio, Texas

前のページへ 次のページへ
任意団体JBCRG 研究業績